Reference
1. Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R (2019) FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clin Cancer Res . 25(11):3205-3209. doi:10.1158/1078-0432.CCR-18-3749
2. Yang H, Ye D, Guan KL, Xiong Y (2012) IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Clin Cancer Res . 18(20): 5562-5571. doi:10.1158/1078-0432.CCR-12-1773
3. Parsons DW, Jones S, Zhang X, et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science . 321(5897):1807-1812. doi:10.1126/science.1164382
4. Turkalp Z, Karamchandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol . 71(10):1319-1325. doi:10.1001/jamaneurol.2014.1205
5. Mondesir J, Willekens C, Touat M, de Botton S (2016) IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med . 7:171-180. doi:10.2147/JBM.S70716
6. Mellinghoff IK, Touat M, Maher E, DeLaFuente M, Cloughesy TF, Holdhoff M, Cote G, et al.(2016) ACTR-46. AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Results from the phase 1 glioma expansion cohorts. Neuro Oncol . 18:vi12.
7. Mellinghoff I, Penas-Prado M, Peters K, Cloughesy T, Burris H, Maher E, Janku F, et al (2018) ACTR-31. Phase 1 study of AG-881, an inhibitor of mutant IDH1 and IDH2: Results from the recurrent/progressive glioma population. Neuro Oncol. 20:vi18.
8. Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, et al (2017) Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol.133:629-644. doi:10.1007/s00401-017-1677-y